Citadel Advisors’s Candel Therapeutics CADL Stock Holding History

Citadel Advisors’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,400	Closed	-$121K	–	13064
2025 Q4	$121K	Sell	21,400 -11,900	-36%	-$64K	﹤0.01%	11490
2025 Q3	$170K	Sell	33,300 -4,300	-11%	-$24.8K	﹤0.01%	11429
2025 Q2	$190K	Sell	37,600 -10,300	-22%	-$53K	﹤0.01%	10723
2025 Q1	$271K	Sell	47,900 -66,600	-58%	-$544K	﹤0.01%	9818
2024 Q4	$994K	Buy	114,500 +88,900	+347%	+$525K	﹤0.01%	7037
2024 Q3	$177K	Buy	25,600 +11,300	+79%	+$70.2K	﹤0.01%	10321
2024 Q2	$88.7K	Buy	+14,300	New	+$107K	﹤0.01%	11084

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's CADL Position: Q1 2026 in Review

Citadel Advisors reduced its Candel Therapeutics (CADL) stake by 68% in Q1 2026, selling an estimated $836K and leaving 72,666 shares worth $356K. The position accounts for ﹤0.01% of the portfolio, ranked #10084.

Citadel Advisors first reported a position in CADL in Q3 2022 and has held it in 10 quarters since. The position peaked at $2.53M in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

Citadel Advisors held 72,666 shares of Candel Therapeutics worth $356K as of Q1 2026.
Citadel Advisors sold 153,690 Candel Therapeutics shares in Q1 2026, an estimated $836K.
Candel Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10084 holding.
Citadel Advisors first reported a position in Candel Therapeutics in Q3 2022 and has held it in 10 quarters since.
Citadel Advisors's Candel Therapeutics position peaked at $2.53M in Q4 2024.
114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.